A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme

Background/Aim: In a previous study investigating radiotherapy for newly diagnosed glioblastoma multiforme (GBM), significant or almost significant associations with survival were found for performance status, upfront resection, 0 6 -methylguanine-DNA methyl-transferase (MGMT) promoter methylation and unifocal GBM. This study aimed to create a survival score based on these factors. Patients and Methods: Most of the 81 patients included received resection of GBM followed by radiochemotherapy (59.4 Gy/33 or 60 Gy/30 fractions). The previously identified predictors of survival were re-evaluated. Factors significantly associated with survival were used for the score. Results: All factors were significantly associated with survival. For each factor, 0 points (less f avorable survival) or 1 point (more favorable survival) were assigned and added for each patient. Three groups were designed, 0-1 (n=10), 2 (n=21) and 3-4 points (n=50); 12-month survival rates were 0%, 38% and 78% (p<0.001). Conclusion: A new survival score was created for patients requiring radiotherapy for GBM that can improve treatment personalization.

Automated summary

A new survival score was developed for GBM patients receiving radiotherapy, based on factors like performance status, upfront resection, MGMT promoter methylation, and unifocal GBM. This score was significantly associated with patient survival rates, enabling improved treatment personalization.